AAV Infection: Protection from Cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Human Gene Therapy

• Publication date

  2017-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.2016.147PMID 27832705PMCID PMC5399746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV.

  2016cited by this paper
• Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector

  2016cited by this paper
• Reply to "Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV".

  2016cited by this paper
• Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma

  2016cited by this paper
• In vivo tissue-tropism of adeno-associated viral vectors.

  2016cited by this paper
• Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses

  2016cited by this paper
• Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.

  2016cited by this paper
• Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients.

  2016cited by this paper
• Adeno-Associated Virus 2-Mediated Hepatocellular Carcinoma is Very Rare in Korean Patients

  2016cited by this paper
• AAV2 and Hepatocellular Carcinoma

  2016cited by this paper
• Adeno-associated virus finds its disease

  2015cited by this paper
• Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.

  2015cited by this paper
• Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas

  2015influential reference
• Adeno-associated Vector Toxicity-To Be or Not to Be?

  2015cited by this paper
• Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?

  2015cited by this paper
• Recombinant Adeno-Associated Virus Integration Sites in Murine Liver After Ornithine Transcarbamylase Gene Correction

  2013cited by this paper
• A largely random AAV integration profile after LPLD gene therapy

  2013influential reference
• No tumour-initiating risk associated with scAAV transduction in newborn rat liver

  2013cited by this paper
• Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity.

  2012cited by this paper
• rAAV-mediated tumorigenesis: still unresolved after an AAV assault.

  2012cited by this paper
• Gene therapy: Progress in childhood disease

  2012cited by this paper
• Induction of hepatocellular carcinoma by in vivo gene targeting

  2012cited by this paper
• Assessing the potential for AAV vector genotoxicity in a murine model.

  2011cited by this paper
• Adeno-Associated Virus Site-Specific Integration Is Mediated by Proteins of the Nonhomologous End-Joining Pathway

  2009cited by this paper
• Adeno-associated virus Rep78 protein inhibits Hepatitis B virus replication through regulation of the HBV core promoter.

  2009cited by this paper
• Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

  2009cited by this paper
• Site-specific, Rep-mediated integration of the intact β-globin locus in the human erythroleukaemic cell line K562

  2008cited by this paper
• AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma

  2007cited by this paper
• No evidence for tumorigenesis of AAV vectors in a large-scale study in mice.

  2005cited by this paper
• Analysis of site‐specific transgene integration following cotransduction with recombinant adeno‐associated virus and a rep encodingplasmid

  2003cited by this paper
• Pathways of Removal of Free DNA Vector Ends in Normal and DNA-PKcs–Deficient SCID Mouse Hepatocytes Transduced with rAAV Vectors

  2003cited by this paper
• Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle

  2003cited by this paper
• Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS1.

  2002cited by this paper
• Virus-mediated killing of cells that lack p53 activity.

  2001influential reference
• Achilles' heel of cancer?

  2001cited by this paper
• Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia.

  2001cited by this paper
• Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors

  2001cited by this paper
• Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue.

  2001cited by this paper
• Virus-mediated killing of cells that lack p53 activity

  2001cited by this paper
• Evaluation of the possible protective role of adeno-associated virus type 2 infection in HPV-associated premalignant disease of the cervix.

  2000cited by this paper
• Binding of the human papillomavirus type 16 E7 oncoprotein and the adeno-associated virus Rep78 major regulatory protein in vitro and in yeast and the potential for downstream effects.

  2000cited by this paper
• Binding of the Human Papillomavirus Type 16 p97 Promoter by the Adeno-associated Virus Rep78 Major Regulatory Protein Correlates with Inhibition*

  1999cited by this paper
• Adeno‐associated virus and development of cervical neoplasia

  1999cited by this paper
• Involvement of protein-DNA interaction in adeno-associated virus Rep78-mediated inhibition of HIV-1.

  1998cited by this paper
• Inhibition/stimulation of bovine papillomavirus by adeno-associated virus is time as well as multiplicity dependent.

  1998cited by this paper
• Lack of Site-Specific Integration of the Recombinant Adeno-Associated Virus 2 Genomes in Human Cells

  1997cited by this paper
• Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro

  1997cited by this paper
• Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric.

  1997cited by this paper
• Adeno-Associated Virus Rep78 Inhibits Oncogenic Transformation of Primary Human Keratinocytes by a Human Papillomavirus Type 16-rasChimeric

  1997cited by this paper
• Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome

  1997cited by this paper
• Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.

  1996cited by this paper
• The regulatory rep protein of adeno-associated virus binds to sequences within the c-H-ras promoter.

  1994cited by this paper
• Down-regulation of the human c-fos and c-myc proto-oncogene promoters by adeno-associated virus Rep78.

  1994cited by this paper
• Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer.

  1994cited by this paper
• Characterization of a preferred site on human chromosome 19q for integration of adeno‐associated virus DNA by non‐homologous recombination.

  1992cited by this paper
• Inhibition of bovine papillomavirus plasmid DNA replication by adeno-associated virus.

  1992cited by this paper
• Inhibition of cellular transformation by the adeno-associated virus rep gene.

  1991cited by this paper
• Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter.

  1991cited by this paper
• Targeted integration of adeno‐associated virus (AAV) into human chromosome 19.

  1991cited by this paper
• Inhibition of H-ras expression by the adeno-associated virus Rep78 transformation suppressor gene product.

  1991cited by this paper
• Site-specific integration by adeno-associated virus.

  1990cited by this paper
• Site-specific integration by adeno-associated virus.

  1990cited by this paper
• The adeno-associated virus Rep78 gene inhibits cellular transformation induced by bovine papillomavirus.

  1989cited by this paper
• Effect of adeno-associated virus on transformation of NIH 3T3 cells by ras gene and on tumorigenicity of an NIH 3T3 transformed cell line.

  1986cited by this paper
• Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus.

  1981cited by this paper
• Inhibition of adenovirus oncogenicity in hamsters by adeno-associated virus DNA.

  1981cited by this paper
• Molecular structure of adeno-associated virus variant DNA.

  1980cited by this paper
• Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults.

  1976cited by this paper
• Effect of adeno-associated virus on cancer expression by herpesvirus-transformed hamster cells.

  1975cited by this paper
• Influence of adeno-associated satellite virus on adenovirus-induced tumours in hamsters.

  1973cited by this paper
• Inhibition of Adenovirus Transformation in Vitro by AAV-1 1

  1972cited by this paper
• A seroepidemiologic study of adenovirus-associated virus infection in infants and children.

  1971cited by this paper
• Inhibition of Adenovirus 12 Oncogenicity by Adeno-Associated Virus

  1968cited by this paper
• Adenovirus-Associated Defective Virus Particles

  1965cited by this paper
• Raav-mediated Tumorigenesis: Still Unresolved after an Aav Assault

  year unknowncited by this paper

• Identification of a novel neutralization epitope in rhesus AAVs

  2024cites this paper
• Stem cell therapeutics and gene therapy for neurologic disorders

  2024cites this paper
• Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies

  2023cites this paper
• Gene therapy for liver diseases — progress and challenges

  2023cites this paper
• Adeno-Associated Virus 2 and Human Adenovirus F41 in Wastewater during Outbreak of Severe Acute Hepatitis in Children, Ireland

  2023cites this paper
• The significance of triple-capsid-mutant AAV8 for treatment of Sanfilippo Syndrome Type B

  2022cites this paper
• Evaluating the state of the science for adeno-associated virus integration: An integrated perspective

  2022cites this paper
• A Systematic Review and Meta-Analyses of Interventional Clinical Trial Studies for Gene Therapies for the Inherited Retinal Degenerations (IRDs)

  2021cites this paper
• Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis

  2021cites this paper
• Cellular, Tissue, and Gene Therapies Advisory Committee September 2-3, 2021 Meeting Briefing Document- FDA

  2021cites this paper
• AAV Vectors: Are They Safe?

  2020cites this paper
• The Challenge of Gene Therapy for Neurological Diseases: Strategies and Tools to Achieve Efficient Delivery to the Central Nervous System

  2020cites this paper
• A Tribute to Barrie J. Carter

  2020cites this paper
• Molecular Approaches for the Treatment of Pompe Disease

  2019cites this paper
• Adeno-associated virus vector as a platform for gene therapy delivery

  2019cites this paper
• Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality.

  2019cites this paper
• Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

  2019cites this paper
• A Genome-Wide Knock-Out Screen Identifies Novel Host Cell Entry Factor Requirements for Divergent Adeno-Associated Virus Serotypes

  2019cites this paper
• Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse

  2019cites this paper
• Position statement of the ZKBS on risk assessment of human adeno-associated viruses and its derived vectors Adeno-associated viruses

  2019cites this paper
• miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression

  2018cites this paper
• Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair

  2018cites this paper
• Gene therapy for hemophilia: what does the future hold?

  2018cites this paper
• Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes

  2018cites this paper
• Re: Srivastava A, Carter BJ; AAV Infection: Protection from Cancer; Hum Gene Ther 2017;28:323–327; DOI: 10.1089/hum.2016.147

  2017cites this paper
• Latest trends in cancer therapy applying viral vectors

  2017cites this paper
• Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model

  2017cites this paper
• AAV: An Overview of Unanswered Questions

  2017cites this paper
• Authors' Response to Jesse D. Riordan, Hum Gene Ther 2017;28:375–376; DOI: 10.1089/hum.2017.045

  2017cites this paper
• Steerable Induction of the Thymosin β4/MRTF-A Pathway via AAV-Based Overexpression Induces Therapeutic Neovascularization

  2017cites this paper
• CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice

  2017cites this paper
• Human Bocavirus 1 Is a Novel Helper for Adeno-associated Virus Replication

  2017cites this paper
• A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line.

  2017cites this paper
• Carcinome hépatocellulaire et hépatocarcinogenèse virale

  2017cites this paper